Up-regulated membrane and nuclear leukotriene B4 receptors in COPD.

STUDY OBJECTIVES We investigated the role of two leukotriene B4 (LTB4) receptors, BLT1 and peroxisome proliferator-activated receptor (PPAR)-alpha, in conferring the susceptibility to develop COPD in smokers. Proinflammatory LTB4 activities are mediated by BLT1, while the inactivation of LTB4 is promoted by PPARalpha. PATIENTS AND METHODS BLT1 and PPARalpha proteins were quantified by immunohistochemistry in specimens obtained during lung surgery from 19 smokers with or without COPD and from 7 nonsmoking subjects. RESULTS We have shown that the percentages of PPARalpha-positive alveolar macrophages and PPARalpha-positive cells in the alveolar wall were increased in COPD patients compared with control subjects. Moreover, the patients with COPD exhibited a significant increase of BLT1-positive alveolar macrophages compared with nonsmokers and an increased number of BLT1-positive cells in the alveolar walls compared with non-COPD smokers. In contrast, BLT1 and PPARalpha immunoreactivity did not differ significantly between nonsmokers and non-COPD smokers. Most of BLT1-positive cells in the alveolar walls were neutrophils and CD8 cells. While the number of neutrophils infiltrating the lung parenchyma was similar among the three groups, the number of CD8 T cells was increased in COPD patients, but there was no evidence that BLT1 was up-regulated specifically on these cells in COPD patients. CONCLUSION The results demonstrated that BLT1 and PPARalpha are detectable in alveolar macrophages and CD8 T cells in human lung tissue, and suggest that the dual LTB4 receptor system is up-regulated in the peripheral lungs of smokers who are susceptible to the development of COPD. This system might represent a novel target for therapeutic intervention in COPD patients.

[1]  M. Belvisi,et al.  PPAR‐γ agonists as therapy for diseases involving airway neutrophilia , 2004, European Respiratory Journal.

[2]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[3]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[4]  P. Barnes,et al.  New concepts in chronic obstructive pulmonary disease. , 2003, Annual review of medicine.

[5]  P. Marrack,et al.  Mast cell–dependent migration of effector CD8+ T cells through production of leukotriene B4 , 2003, Nature Immunology.

[6]  J. Auwerx,et al.  Peroxisome Proliferator–activated Receptors α and γ Down-regulate Allergic Inflammation and Eosinophil Activation , 2003, The Journal of experimental medicine.

[7]  A. Tager,et al.  BLT1 and BLT2: the leukotriene B(4) receptors. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[8]  P. Montuschi,et al.  CT-guided pleural biopsy preferable to traditional Abram’s needle in diagnosing malignant pleural disease , 2003, Thorax.

[9]  L. Fabbri,et al.  Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients , 2003, European Respiratory Journal.

[10]  B. Balbi COPD: is chemotaxis the key? , 2003, Chest.

[11]  P. Barnes,et al.  Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. , 2003, Chest.

[12]  P. Barnes,et al.  Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD , 2003, Thorax.

[13]  Dallas Jones,et al.  Emerging roles of PPARS in inflammation and immunity , 2002, Nature Reviews Immunology.

[14]  I. Adcock,et al.  Increased expression of nuclear factor-κB in bronchial biopsies from smokers and patients with COPD , 2002, European Respiratory Journal.

[15]  R. Stockley,et al.  Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of α1–antitrypsin deficiency and the role of leukotriene B4 and interleukin 8 , 2002, Thorax.

[16]  B. Beghé,et al.  Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. , 2002, American journal of respiratory and critical care medicine.

[17]  T. Betsuyaku,et al.  Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema , 2002, Thorax.

[18]  Y. Terauchi,et al.  Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. , 2001, The Journal of clinical investigation.

[19]  L. Fabbri,et al.  Increased expression of heme oxygenase (HO)-1 in alveolar spaces and HO-2 in alveolar walls of smokers. , 2001, American journal of respiratory and critical care medicine.

[20]  M. Aubier,et al.  Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. , 2001, American journal of respiratory and critical care medicine.

[21]  P. Paré,et al.  Amplification of inflammation in emphysema and its association with latent adenoviral infection. , 2001, American journal of respiratory and critical care medicine.

[22]  R. Stockley,et al.  Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. , 2001, The European respiratory journal.

[23]  T. Shimizu,et al.  Leukotriene B4: metabolism and signal transduction. , 2001, Archives of biochemistry and biophysics.

[24]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[25]  L. Fabbri,et al.  Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. , 2000, American journal of respiratory and critical care medicine.

[26]  R. Stockley,et al.  The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. , 1999, American journal of respiratory and critical care medicine.

[27]  M. Lazar,et al.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.

[28]  L. Fabbri,et al.  Severity of airflow limitation is associated with severity of airway inflammation in smokers. , 1998, American journal of respiratory and critical care medicine.

[29]  A. Luster,et al.  Molecular and Biological Characterization of the Murine Leukotriene B4 Receptor Expressed on Eosinophils , 1998, The Journal of experimental medicine.

[30]  P. Colville-Nash,et al.  Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. , 1998, Journal of immunology.

[31]  L. Fabbri,et al.  CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[32]  L. Fabbri,et al.  Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. , 1997, American journal of respiratory and critical care medicine.

[33]  P. Jeffery,et al.  Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. , 1997, American journal of respiratory and critical care medicine.

[34]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[35]  L. Fabbri,et al.  Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. , 1996, Thorax.

[36]  L. Fabbri,et al.  Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. , 1996, American journal of respiratory and critical care medicine.

[37]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[38]  S. Chinn Statistics in respiratory medicine. 2. Repeatability and method comparison. , 1991, Thorax.